Assessing basophil functional measures during monoclonal anti-IgE therapy

Research output: Contribution to journalReview article

Abstract

Assessing the impact of therapeutic interventions on the clinical and immunologic responses of allergic subjects is a topic of extensive investigation. Available approaches include the measurement of in vivo allergen challenge responses, serologic measures, or in vitro studies of cells that participate in the allergic reaction. Several decades of work support that measures of allergen responses of IgE-bearing peripheral blood basophils can reflect clinical expression of allergic disease. In the last decade, an immune-based therapy targeting IgE, omalizumab, has emerged as an adjunct treatment for a variety of allergic diseases. This monoclonal humanized IgG antibody specifically binds circulating IgE at a region in the Fc tail that prevents IgE attachment to high affinity IgE receptor (FcεRI) bearing cell types such as tissue mast cells and blood basophils. This review focuses on methods to monitor changes of basophil allergen reactivity with a focus on omalizumab therapy and the implications for clinical disease management.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalJournal of Immunological Methods
Volume383
Issue number1-2
DOIs
StatePublished - Sep 28 2012

Keywords

  • Basophils
  • IgE
  • Omalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Assessing basophil functional measures during monoclonal anti-IgE therapy'. Together they form a unique fingerprint.

  • Cite this